Prolyl hydroxylase domain (PHD) proteins play a major role in regulating the hypoxia-inducible factor (HIF) that induces expression of genes involved in angiogenesis, erythropoiesis, and cell metabolism, proliferation, and survival. Germ-line mutations in the prolyl hydroxylase domain 2 gene (PHD2) have been reported in patients with familial erythrocytosis but not in association with tumors. We describe a patient with erythrocytosis and recurrent paraganglioma who carries a newly discovered PHD2 mutation. This mutation affects PHD2 function and stabilizes HIF-alpha proteins. In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMoa0806277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EGLN1 mutations in Cis can induce congenital erythrocytosis with thromboses by increasing protein instability.
Br J Haematol
January 2025
Laboratoire de Cytologie Clinique et Cytogénétique, LBMR néoplasies myéloprolifératives, CHU CAREMEAU, Nîmes, France.
Hereditary congenital erythrocytosis results from constitutive activation of the hypoxia pathway. This pathway is controlled by regulation of the α isoforms of the hypoxia-inducible factor α/β heterodimer, notably via hydroxylation by prolyl hydroxylase domain 2 (PHD2). Mutations affecting PHD2 are involved in Type 3 erythrocytosis.
View Article and Find Full Text PDFMetabolic and Immunological Implications of MMECAF-Mediated Hypoxia Signaling in Pancreatic Cancer Progression: Therapeutic Insights and Translational Opportunities.
Biol Proced Online
September 2024
Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Department of Integrative Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
Article Synopsis
- * This research identified a specific fibroblast subpopulation, MMECAFs, expressing the Membrane Metalloendopeptidase, using single-cell transcriptome sequencing and various screening methods related to tumor characteristics.
- * Findings suggest that MMECAFs play critical roles in promoting cancer through hypoxia-related signaling and inflammatory pathways, and their high expression correlates with worse patient survival rates, indicating potential targets for therapy.
PHD2 enzyme is an intracellular manganese sensor that initiates the homeostatic response against elevated manganese.
Proc Natl Acad Sci U S A
June 2024
Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712.
Intracellular sensors detect changes in levels of essential metals to initiate homeostatic responses. But, a mammalian manganese (Mn) sensor is unknown, representing a major gap in understanding of Mn homeostasis. Using human-relevant models, we recently reported that: 1) the primary homeostatic response to elevated Mn is upregulation of hypoxia-inducible factors (HIFs), which increases expression of the Mn efflux transporter SLC30A10; and 2) elevated Mn blocks the prolyl hydroxylation of HIFs by prolyl hydroxylase domain (PHD) enzymes, which otherwise targets HIFs for degradation.
View Article and Find Full Text PDFASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
Nat Commun
June 2024
Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Article Synopsis
- MLL4 and MLL3 are proteins often mutated in cancer that modify histones, specifically monomethylating histone H3K4, and contain unexplored PHD finger domains.
- The PHD2 and PHD3 fingers of MLL4 and MLL3 interact with ASXL2, a component of the PR-DUB complex, which plays a role in regulating histone modifications.
- Analysis shows that the MLL3/4 and PR-DUB complexes work together in a way that relies on the binding of ASXL1/2, which is essential for recruiting the deubiquitinase BAP1 to active enhancers in embryonic stem cells.
DPF2-related Coffin-Siris syndrome type 7 in two generations.
Eur J Med Genet
June 2024
Institute of Medical Genetics, University of Zurich, Switzerland.
To date 11 patients with Coffin-Siris syndrome type 7 (OMIM 618027) have been described since the first literature report. All reported patients carried de novo variants with presumed dominant negative effect, which localized in the PHD1/PHD2 domains of DPF2. Here we report on the first familial case of Coffin-Siris syndrome type 7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!